Airway inflammation and eotaxin in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy

Ayres, 2004, Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma, Allergy., 59, 701, 10.1111/j.1398-9995.2004.00533.x Gonlugur, 2004, Vascular adhesion and transendothelial migration of eosinophil leukocytes, Cell Tissue Res., 318, 473, 10.1007/s00441-004-0925-3 Tai, 1991, Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro, Clin Exp Immunol., 85, 312, 10.1111/j.1365-2249.1991.tb05725.x Miotto, 2001, Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases, J Allergy Clin Immunol., 107, 664, 10.1067/mai.2001.113524 Luster, 1998, Chemokines–chemotactic cytokines that mediate inflammation, N Engl J Med., 338, 436, 10.1056/NEJM199802123380706 Platts-Mills, 2001, The role of immunoglobulin E in allergy and asthma, Am J Respir Crit Care Med., 164, S1, 10.1164/ajrccm.164.supplement_1.2103024 Global Initiative for Asthma. Global strategy for asthma management and prevention: NHLBI/WHO Report 2006; Publication 02-3569. Hochhaus, 2003, Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma, Curr Med Res Opin., 19, 491, 10.1185/030079903125002171 American Thoracic Society/American Lung Association, 1999, Am J Respir Crit Care Med., 160, 2104, 10.1164/ajrccm.160.6.ats8-99 American Thoracic Society, 1991, Lung function testing: selection of reference values and interpretative strategies, Am Rev Respir Dis., 144, 1202, 10.1164/ajrccm/144.5.1202 Horváth, 2005, Exhaled breath condensate: methodological recommendations and unresolved questions, Eur Respir J., 26, 523, 10.1183/09031936.05.00029705 Prussin, 2003, IgE, mast cells, basophils, and eosinophils, J Allergy Clin Immunol., 111, S486, 10.1067/mai.2003.120 Adamko, 2005, The rise of the phoenix: the expanding role of the eosinophil in health and disease, Allergy., 60, 13, 10.1111/j.1398-9995.2005.00676.x Hamelmann, 2007, The rationale for treating allergic asthma with anti-IgE, Eur Respir Rev., 16, 61, 10.1183/09059180.00010401 Humbert, 2005, Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy., 60, 309, 10.1111/j.1398-9995.2004.00772.x Djukanović, 2004, Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma, Am J Respir Crit Care Med., 170, 583, 10.1164/rccm.200312-1651OC Holgate, 2005, The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation, J Allergy Clin Immunol., 115, 459, 10.1016/j.jaci.2004.11.053 Foroughi, 2007, Anti-IgE treatment of eosinophil-associated gastrointestinal disorders, J Allergy Clin Immunol., 120, 594, 10.1016/j.jaci.2007.06.015 Palframan, 1998, Eotaxin induces a rapid release of eosinophils and their progenitors from the bone marrow, Blood., 91, 2240, 10.1182/blood.V91.7.2240 Woo, 2002, Eotaxin induces migration of RBL-2H3 mast cells via a Rac-ERK-dependent pathway, Biochem Biophys Res Commun., 298, 392, 10.1016/S0006-291X(02)02432-4 Uguccioni, 1997, High expression of the chemokine receptor CCR3 in human blood basophils. Role in activation by eotaxin, MCP-4, and other chemokines, J Clin Invest., 100, 1137, 10.1172/JCI119624 Miller, 2008, Severe asthma and the omalizumab option, Clin Mol Allergy., 6, 4, 10.1186/1476-7961-6-4 Zietkowski, 2011, RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy, Int Arch Allergy Immunol., 154, 25, 10.1159/000319205 Zietkowski, 2010, Anti-IgE therapy with omalizumab decreases endothelin-1 in exhaled breath condensate of patients with severe persistent allergic asthma, Respiration., 80, 534, 10.1159/000317137 Mochizuki, 1998, IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy, J Immunol., 160, 60, 10.4049/jimmunol.160.1.60 Teran, 1999, Th1- and Th2-type cytokines regulate the expression and production of eotaxin and RANTES by human lung fibroblasts, Am J Respir Cell Mol Biol., 20, 777, 10.1165/ajrcmb.20.4.3508